A nationwide survey on participation in cardiac rehabilitation among patients with coronary heart disease using health claims data in Japan.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 10 2021
Historique:
received: 24 05 2021
accepted: 22 09 2021
entrez: 12 10 2021
pubmed: 13 10 2021
medline: 29 1 2022
Statut: epublish

Résumé

Poor implementation and variable quality of cardiac rehabilitation (CR) for coronary heart disease (CHD) have been a global concern. This nationwide study aimed to clarify the implementation of and participation in CR among CHD patients and associated factors in Japan. We conducted a retrospective cohort study using data extracted from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Patients who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in 2017-2018 were included. Aspects of CR were assessed in terms of (1) participation in exercise-based CR, (2) pharmacological education, and (3) nutritional education. Of 87,829 eligible patients, 32% had participated in exercise-based CR, with a mean program length of 40 ± 71 days. CABG was associated with higher CR participation compared to PCI (OR 10.2, 95% CI 9.6-10.8). Patients living in the Kyushu region were more likely to participate in CR (OR 2.59, 95% CI 2.39-2.81). Among patients who participated in CR, 92% received pharmacological education, whereas only 67% received nutritional education. In Japan, the implementation of CR for CHD is insufficient and involved varying personal, therapeutic, and geographical factors. CR implementation needs to be promoted in the future.

Identifiants

pubmed: 34635704
doi: 10.1038/s41598-021-99516-1
pii: 10.1038/s41598-021-99516-1
pmc: PMC8505519
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20096

Informations de copyright

© 2021. The Author(s).

Références

Circ Rep. 2021 Feb 27;3(3):122-130
pubmed: 33738344
J Diabetes Investig. 2020 Mar;11(2):426-434
pubmed: 31581351
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Prog Cardiovasc Dis. 2014 Mar-Apr;56(5):557-62
pubmed: 24607022
Circulation. 2018 Sep 4;138(10):965-967
pubmed: 30354536
Prog Cardiovasc Dis. 2017 Sep - Oct;60(2):267-280
pubmed: 28844588
Osteoporos Int. 2019 May;30(5):975-983
pubmed: 30648192
Int J Cardiol. 2016 Nov 15;223:436-443
pubmed: 27557484
Eur J Prev Cardiol. 2019 Jul;26(11):1131-1146
pubmed: 30782007
Heart Lung Circ. 2015 May;24(5):430-41
pubmed: 25637253
BMJ Open. 2020 May 5;10(5):e033365
pubmed: 32376747
Heart Lung Circ. 2019 Nov;28(11):1622-1630
pubmed: 30220480
Circ Cardiovasc Qual Outcomes. 2017 Jun;10(6):
pubmed: 28619725
BMJ Open. 2017 Jan 27;7(1):e013036
pubmed: 28132004
Cochrane Database Syst Rev. 2017 Jun 30;6:CD007130
pubmed: 28665511
Plast Reconstr Surg. 2020 Jul;146(1):83-89
pubmed: 32590649
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
Int J Cardiol. 2020 Jan 1;298:1-7
pubmed: 31405584
Am J Med. 2014 Jun;127(6):538-46
pubmed: 24556195
Nat Rev Cardiol. 2014 Oct;11(10):586-96
pubmed: 25027487
Int J Cardiol. 2019 Sep 15;291:183-188
pubmed: 30826193
J Am Coll Cardiol. 2020 Sep 15;76(11):1328-1340
pubmed: 32912447
Eur J Prev Cardiol. 2020 Jun;27(9):912-928
pubmed: 31581808
Int Dent J. 2020 Aug;70(4):308-315
pubmed: 32103503
Am J Trop Med Hyg. 2020 Jun;102(6):1237-1243
pubmed: 32314702
Circ J. 2019 Apr 25;83(5):1085-1196
pubmed: 30930428
Can J Cardiol. 2019 Nov;35(11):1491-1498
pubmed: 31604671
J Cardiopulm Rehabil Prev. 2016 Mar-Apr;36(2):112-6
pubmed: 26252341
Cochrane Database Syst Rev. 2016 Jan 05;(1):CD001800
pubmed: 26730878
Cochrane Database Syst Rev. 2019 Feb 01;2:CD007131
pubmed: 30706942
Circulation. 2007 Oct 9;116(15):1653-62
pubmed: 17893274
Qual Life Res. 2020 Mar;29(3):579-592
pubmed: 31691204
Circ J. 2019 Aug 23;83(9):1819-1821
pubmed: 31391350
J Am Coll Cardiol. 2015 May 19;65(19):2079-88
pubmed: 25975470
Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e000037
pubmed: 29599285
J Cardiopulm Rehabil Prev. 2015 May-Jun;35(3):186-92
pubmed: 25622218
Cochrane Database Syst Rev. 2017 Jun 28;6:CD008895
pubmed: 28658719
Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e005902
pubmed: 31931615
Circ J. 2007 Feb;71(2):173-9
pubmed: 17251662
Circ J. 2017 Sep 25;81(10):1424-1431
pubmed: 28496030
Eur J Prev Cardiol. 2013 Aug;20(4):692-700
pubmed: 23847263
Heart. 2016 Sep 15;102(18):1449-55
pubmed: 27181874

Auteurs

Shosuke Ohtera (S)

Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, 2-3-6 Minami, Wako-shi, Saitama, 351-0197, Japan.

Genta Kato (G)

Solutions Center for Health Insurance Claims, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. qq9f8hn9@kuhp.kyoto-u.ac.jp.

Hiroaki Ueshima (H)

Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Yukiko Mori (Y)

Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Yuka Nakatani (Y)

Department of Health Informatics, Kyoto University School of Public Health, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.

Neiko Ozasa (N)

Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Takeo Nakayama (T)

Department of Health Informatics, Kyoto University School of Public Health, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.

Tomohiro Kuroda (T)

Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH